Clinical review report. Somatropin (Genotropin - Pfizer Canada Inc.) indication: long-term treatment of children who have growth failure due to an inadequate secretion of endogenous growth hormone
CADTH
Record ID 32014000806
English
Authors' recommendations:
The Common Drug Review identified two RCTs in children with GHD that compared Genotropin with other somatropin products available in Canada. The Shih et al. study was considered underpowered to provide meaningful results. Results of the Romer et al. study suggest Genotropin has similar effects on linear growth compared with Omnitrope over a period of nine months. There are insufficient data from the reviewed trials to compare efficacy and safety of Genotropin with other somatropin products available in Canada, particularly related to final height, health-related quality of life, and infrequent or long-latency adverse events.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/media/cdr/clinical/SR0333_GenotropinGHD-P_CL_Report_e.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Growth Disorders
- Human Growth Hormone
- Child
- Body Height
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.